Amisulpride | 阿米舒必利 | DAN 2163 | Dopamine Receptor Antagonist

首页 / / / 多巴胺受体 / Amisulpride

氨磺必利 /Amisulpride {[allProObj[0].p_purity_real_show]}

货号：A517016 同义名： 阿米舒必利 / DAN 2163

Amisulpride is a selective dopamine antagonist wit Ki of 2.8 nM for D2 receptor and Ki of 3.2 nM D3 receptor, it's used as an antipsychotic drug.

Amisulpride 化学结构
CAS号：71675-85-9

Amisulpride 3D分子结构
CAS号：71675-85-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Amisulpride 纯度/质量文件产品仅供科研

货号：A517016 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

多巴胺受体亚型比较

产品名称	D1 receptor ↓ ↑	D2 receptor ↓ ↑	D3 receptor ↓ ↑	D4 receptor ↓ ↑	D5 receptor ↓ ↑	DAT ↓ ↑	Dopamine receptor ↓ ↑	其他靶点	纯度
Penfluridol	+ Dopamine receptor, Ki: 1.6 μM								98%
Ansofaxine HCl	++ Dopamine receptor, IC50: 491 nM								98%
Tetrahydroberberine,THB		+ D2 receptor, pKi: 6.08							98+%
Prochlorperazine Maleate		✔							95%
Olanzapine		✔							99+%
Trifluoperazine		++++ Dopamine D2 receptor, IC50: 1.1 nM							98%
Ropinirole hydrochloride		++ D2 receptor, Ki: 29 nM							99%
Lurasidone		++++ D2 receptor, Ki: 1 nM							98%
Levosulpiride		✔							99+%
Pridopidine		✔							95%
Metoclopramide		✔					✔		99+%
Molindone HCl		✔							98%
Sulpiride		✔							99+%
Perospirone		++++ D2 receptor, Ki: 1.4 nM							99%
Perospirone HCl		++++ D2 receptor, Ki: 1.4 nM							98+%
Phenothiazine		✔							98%
Pimozide	+ Dopamine D1 receptor, Ki: 6600 nM	+++ Dopamine D2 receptor, Ki: 3.0 nM	++++ Dopamine D3 receptor, Ki: 0.83 nM						98%
Rotundine	++ D1 receptor, IC50: 166 nM	+ D2 receptor, IC50: 1.47 μM	+ D3 receptor, IC50: 3.25 μM						98%
Domperidone		✔							99+%
ONC206		✔							97%
Pimethixene maleate	++ Dopamine D1 Receptor, pKi: 6.37	+++ Dopamine D2 Receptor, pKi: 8.19		++ Dopamine D4.4 Receptor, pKi: 7.54					97%
Loxapine succinate	++ D1 receptor (human), Ki: 26 nM D2 receptor (Human), Ki: 62 nM	++ D2 receptor (human), Ki: 24 nM D2 receptor (bovine), Ki: 26 nM		+++ D4 receptor (human), Ki: 7.5 nM					99%
Chlorprothixene	+++ D1 receptor, Ki: 18 nM	+++ D2 receptor, Ki: 2.96 nM	+++ D3 receptor, Ki: 4.56 nM		+++ D5 receptor, Ki: 9 nM				98%
SCH-23390 HCl	++++ D1 dopamine receptor, Ki: 0.2 nM				++++ D5 dopamine receptor, Ki: 0.3 nM				98%
MPP+ iodide						✔			97%
σ1 Receptor antagonist-1						+ DAT, pKi: 5.8			97%
Benztropine mesylate						++ DAT, IC50: 118 nM			98%
Azaperone							✔		98%
Ziprasidone HCl							✔		98+%
Paliperidone							✔		98%
Alizapride HCl							✔		99+%
Amisulpride							✔		98%
Quetiapine hemifumarate							✔	Adrenergic Receptor	98%
Clozapine N-oxide							✔		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Amisulpride 生物活性

靶点

Dopamine receptor

描述

Amisulpride as a specific dopamine receptor antagonist with high and similar affinity for the dopamine D2 and D3 receptor. In vitro, amisulpride has high affinity and selectivity for the human dopamine D2 (Ki = 2.8 nM) and D3 (Ki = 3.2 nM) receptors. Amisulpride has high affinity and selectivity for the human dopamine D2 (Ki = 2.8 nM) and D3 (Ki = 3.2 nM) receptors. At low doses (< or = 10 mg/kg) amisulpride preferentially blocks presynaptic dopamine autoreceptors that control dopamine synthesis and release in the rat, whereas at higher doses (40-80 mg/kg) postsynaptic dopamine D2 receptor occupancy and antagonism is apparent^[3]. Amisulpride has an antidepressant like activity comparable to that of olanzapine though the activity was significantly less than that of fluoxetine^[4]. Amisulpride 400 to 800 mg/day was more effective than haloperidol, risperidone and flupenthixol in controlling affective symptoms in these patients. In randomised, double-blind trials involving patients with predominantly negative symptoms of schizophrenia, amisulpride 50 to 300 mg/day was more effective than placebo. Amisulpride is effective as maintenance therapy in patients with chronic schizophrenia. Long-term treatment with amisulpride was associated with improvements in quality of life and social functioning. Amisulpride is generally well tolerated^[5]. Low-dose amisulpride is effective and well tolerated as a treatment for VLOSLP (Very late-onset (aged ≥ 60 years) schizophrenia-like psychosis), with benefits maintained by prolonging treatment. Potential adverse events include clinically significant extrapyramidal symptoms and falls^[6].

Amisulpride 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01323205	Schizophrenia	Phase 2	Completed	-	Austria ... 展开 >> Innsbruck, Austria Salzburg, Austria Wien, Austria Belgium Dave, Belgium Duffel, Belgium Kortenberg, Belgium Lede, Belgium Bulgaria Plovdiv, Bulgaria Radnevo N/A, Bulgaria Germany Berlin, Germany Hamburg, Germany Mainz, Germany Mannheim, Germany München, Germany Romania Arad, Romania Brasov, Romania Iasi, Romania Sibiu, Romania Spain Barcelona, Spain Zamora, Spain 收起 <<
NCT02374567	Dementia Depr... 展开 >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders 收起 <<	Phase 3	Terminated	-	Germany ... 展开 >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany 收起 <<
NCT02855229	-		Recruiting	March 2020	United States, Massachusetts ... 展开 >> McLean Hospital Recruiting Belmont, Massachusetts, United States, 02478 Contact: David J Crowley, ALM 800-333-0338 ext 4432 neurolab@mclean.harvard.edu Principal Investigator: Diego A Pizzagalli, PhD 收起 <<

Amisulpride 参考文献

[1]Sarkhel S, Praharaj SK, et al. Amisulpride-induced macrocytic anemia. J Neuropsychiatry Clin Neurosci. 2013 Winter;25(1):E10-1.

[2]Schoemaker H, Claustre Y, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997 Jan;280(1):83-97.

[3]Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280(1):83‐97

[4]Pawar GR, Agrawal RP, Phadnis P, Paliwal A, Vyas S, Solanki P. Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice. Acta Pol Pharm. 2009;66(3):327‐331

[5]Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs. 2001;61(14):2123‐2150

[6]Reeves S, Eggleston K, Cort E, et al. Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). Int J Geriatr Psychiatry. 2018;33(2):396‐404

Amisulpride 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.53mL

2.71mL

1.35mL

27.07mL

5.41mL

2.71mL

Amisulpride 技术信息

CAS号	71675-85-9
分子式	C₁₇H₂₇N₃O₄S
分子量	369.479

别名	阿米舒必利 ;DAN 2163
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C

溶解度

DMSO: 50 mg/mL(135.33 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01323205	Schizophrenia	Phase 2	Completed	-	Austria ... 展开 >> Innsbruck, Austria Salzburg, Austria Wien, Austria Belgium Dave, Belgium Duffel, Belgium Kortenberg, Belgium Lede, Belgium Bulgaria Plovdiv, Bulgaria Radnevo N/A, Bulgaria Germany Berlin, Germany Hamburg, Germany Mainz, Germany Mannheim, Germany München, Germany Romania Arad, Romania Brasov, Romania Iasi, Romania Sibiu, Romania Spain Barcelona, Spain Zamora, Spain 收起 <<
NCT02374567	Dementia Depr... 展开 >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders 收起 <<	Phase 3	Terminated	-	Germany ... 展开 >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany 收起 <<
NCT02855229	-		Recruiting	March 2020	United States, Massachusetts ... 展开 >> McLean Hospital Recruiting Belmont, Massachusetts, United States, 02478 Contact: David J Crowley, ALM 800-333-0338 ext 4432 neurolab@mclean.harvard.edu Principal Investigator: Diego A Pizzagalli, PhD 收起 <<
NCT02435095	Schizophrenia	Phase 4	Recruiting	April 2019	Germany ... 展开 >> RWTH University Hospital Aachen Recruiting Aachen, NRW, Germany, 52074 Contact: Sabrina Schaffrath saschaffrath@ukaachen.de Contact: Sarah Lammertz slammertz@ukaachen.de Alexianer Aachen GmbH Not yet recruiting Aachen, Germany, 52062 Zentrum für Neurologie und Seelische Gesundheit im Kapuziner Karree Aachen Not yet recruiting Aachen, Germany, 52062 Contact: Frank Bergmann, Dr. med. LVR Klinik Bonn Recruiting Bonn, Germany, 53111 LVR Klinik Düren Not yet recruiting Düren, Germany, 52353 Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität Düsseldorf Recruiting Düsseldorf, Germany, 40629 LVR Klinik Essen Not yet recruiting Essen, Germany, 45147 ViaNobis Gangelt Recruiting Gangelt, Germany, 52538 Klinik Königshof (Abteilung für Allgemeine Psychiatrie) Recruiting Krefeld, Germany, 47807 LVR Klinik Langenfeld Recruiting Langenfeld, Germany, 40764 LVR Klinik Viersen Not yet recruiting Viersen, Germany, 41749 收起 <<
NCT00448630	-		Completed	-	Turkey ... 展开 >> Pfizer Investigational Site Kurttepe, Adana, Turkey, 01360 Pfizer Investigational Site Adana, Turkey Pfizer Investigational Site Ankara, Turkey, 06200 Pfizer Investigational Site Ankara, Turkey Pfizer Investigational Site Antakya, Turkey Pfizer Investigational Site Bolu, Turkey Pfizer Investigational Site Denizli, Turkey Pfizer Investigational Site Elazig, Turkey Pfizer Investigational Site Eskisehir, Turkey Pfizer Investigational Site Istanbul, Turkey, 34147 Pfizer Investigational Site Istanbul, Turkey Pfizer Investigational Site Izmir, Turkey Pfizer Investigational Site Kayseri, Turkey Pfizer Investigational Site Konya, Turkey Pfizer Investigational Site Manisa, Turkey Pfizer Investigational Site Samsun, Turkey Pfizer Investigational Site Trabzon, Turkey Pfizer Investigational Site Trakya, Turkey 收起 <<
NCT02307396	Schizophrenia ... 展开 >> Schizophrenia and Disorders With Psychotic Features Schizoaffective Disorders 收起 <<	Phase 4	Completed	-	Germany ... 展开 >> Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar Munich, Bavaria, Germany, 81675 收起 <<
NCT01765829	Psychosis Nos/Other	Phase 3	Unknown	November 2015	Spain ... 展开 >> Mental Health Unit Villamartín Recruiting Villamartín, Cádiz, Spain, 11650 Contact: José María Mongil San Juan, MD 0034956040209 cheman45@gmail.com Principal Investigator: José María Mongil San Juan, MD Mental Health Unit Baza Recruiting Baza, Granada, Spain, 18800 Contact: Eva Bravo Barba, MD eva.bravo.barba@gmail.com Principal Investigator: Eva Bravo Barba, MD Mental Health Unit Motril Recruiting Motril, Granada, Spain, 18600 Contact: María Luisa Barrigón Estévez, MD 0034958038849 marial.barrigon.sspa@juntadeandalucia.es Principal Investigator: María Luisa Barrigón Estévez, MD Mental Health Unit Andújar Recruiting Andújar, Jaén, Spain, 23740 Contact: Fernando Sarramea Crespo, MD, PhD 0034953021717 fernandosarramea@hotmail.com Principal Investigator: Farnando Sarramea Crespo, MD, PhD Mental Health Unit Martos Recruiting Martos, Jaén, Spain, 23600 Contact: Miguel Ortigosa Luque, MD migueortigosa@hotmail.com Principal Investigator: Miguel Ortigosa Luque, MD Mental Health Unit Miraflores Not yet recruiting Alcobendas, Madrid, Spain, 28100 Contact: María Luisa Zamarro Arraz, MD, PhD 0034916530108 zamarroluisa@yahoo.es Principal Investigator: María Luisa Zamarro Arraz, MD, PhD Hospital Infanta Sofía Not yet recruiting San Sebastian de los Reyes, Madrid, Spain, 28702 Contact: María Rosario Gutiérrez Labrador, MD rosagutierrez@psiquiatra.e.telefonica.net Principal Investigator: María Rosario Guitiérrez Labrador, MD Mental Health Unit Valle del Guadalhorce Not yet recruiting Cártama, Málaga, Spain, 29580 Contact: Daniel Gutiérrez Castillo, MD 0034951033931 dgutierrezcastillo@gmail.com Principal Investigator: Daniel Gutiérrez Castillo, MD Mental Health Unit Las Lagunas Not yet recruiting Fuengiróla, Málaga, Spain, 29650 Contact: María Isabel Osuna Carmona, MD maribelosunac@hotmail.com Principal Investigator: María Isabel Osuna Carmona, MD Fundación Argibide Not yet recruiting Pamplona, Navarra, Spain, 31007 Contact: Ignacio Mata Pastor, MD, PhD 0034948266650 nacho.mata70@gmail.com Principal Investigator: Ignacio Mata Pastor, MD, PhD Hospital El Tomillar Recruiting Dos Hermanas, Seville, Spain, 41700 Contact: Joaquín Carlos Martín Muñoz, MD, PhD 0034955016083 joaquinmartin@hotmail.com Principal Investigator: Joaquín Carlos Martín Muñoz, MD, PhD Hospital Francesc de Borja Recruiting Gandía, Valencia, Spain, 46700 Contact: María Lacruz Silvestre, MD, PhD maria.lacruz.silvestre@gmail.com Principal Investigator: María Lacruz Silvestre, MD, PhD Hospital de Basurto Not yet recruiting Bilbao, Spain, 48013 Contact: Sonia Bustamante Madariaga, MD, Phd 0034944 006137 sonia.bustamantemadariaga@osakidetza.net Principal Investigator: Sonia Bustamante Madariaga, MD, PhD Mental Health Unit Tetuán Not yet recruiting Madrid, Spain, 28003 Contact: Mariano Hernández Monsalve, MD, PhD 0034915347363 hergoico@gmail.com Contact: Ruth Berdún Pe, MD ruthberdun@yahoo.es Principal Investigator: Mariano Hernández Monsalve, MD, PhD Lafora Hospital Not yet recruiting Madrid, Spain, 28049 Contact: Juan Dios Molina Martín, MD, PhD jmolinamar@hotmail.com Principal Investigator: Juan Dios Molina Martín, MD, PhD Hospital Carlos Haya Recruiting Málaga, Spain, 29009 Contact: Fermín Mayoral Cleríes, Md, PhD fermin.mayoral.sspa@juntadeandalucia.es Principal Investigator: Fermín Mayoral Cleríes, MD, PhD Virgen del Rocío Hospital Recruiting Seville, Spain, 41013 Contact: Clara M. Rosso Fernández, MD 0034955013414 claram.rosso.sspa@juntadeandalucia.es Contact: Miguel Ruiz Veguilla, MD, PhD 0034955013414 mruizveguilla@yahoo.com Principal Investigator: Miguel Ruiz Veguilla, MD, PhD 收起 <<
NCT01498770	-		Completed	-	-
NCT01280396	-		Completed	-	Hong Kong ... 展开 >> Western Psychiatric Centre Hong Kong, Hong Kong, 00000 收起 <<
NCT00448630	-		Completed	-	-
NCT02640911	-		Recruiting	May 2021	China, Shanghai ... 展开 >> Shanghai Mental Health Center Recruiting Shanghai, Shanghai, China, 200030 Contact: Huafang Li, PH.D 86-2134773128 lhlh_5@163.com 收起 <<
NCT02088060	Schizophrenia	Phase 2	Active, not recruiting	December 2021	Denmark ... 展开 >> Psychiatric Centre Glostrup Glostrup, Denmark, 2600 Germany Department of General Psychiatry, Heidelberg University Heidelberg, BW, Germany, 68115 Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health Mannheim, BW, Germany, 68159 Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich Munich, BY, Germany, 80336 Dept. of Psychiatry and Psychotherapy, Technical University Munich Munich, BY, Germany, 81675 Dept. of Psychiatry and Psychotherapy, Martin-Luther-University, Halle/Wittenberg Halle, Saint, Germany, 06112 收起 <<
NCT00304616	Schizophrenia	Phase 4	Completed	-	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Korea, Republic of, 138-736 收起 <<
NCT01714011	Schizophrenia	Phase 4	Completed	-	Malaysia ... 展开 >> University Malaya Medical Centre Kuala Lumpur, Malaysia, 59100 收起 <<
NCT03510325	Schizophrenia	Phase 4	Not yet recruiting	September 1, 2021	China, Shanghai ... 展开 >> Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China, 200030 收起 <<
NCT02222220	Clozapine-induced Hypersalivat... 展开 >>ion 收起 <<	Phase 3	Completed	-	Israel ... 展开 >> Be'er Sheva Mental Health Center, Be'er Sheva, Israel, 8417000 收起 <<
NCT03451734	-		Recruiting	December 31, 2020	China, Hunan ... 展开 >> Mental Health Institute of 2nd Xiangya Hospital,CSU Recruiting Changsha, Hunan, China, 410011 Contact: Renrong Wu, PhD 15874179855 wurenrong2013@163.com 收起 <<
NCT02051387	Schizophrenia	Phase 1	Completed	-	Germany ... 展开 >> Central Institute of Mental Health Mannheim, BW, Germany, 68159 Dept. of Pharmacology, University of Cologne Cologne, NRW, Germany, 50931 收起 <<
NCT02449291	Postoperative Nausea and Vomit... 展开 >>ing 收起 <<	Phase 3	Completed	-	United States, Florida ... 展开 >> Jackson Memorial Hospital Miami, Florida, United States, 33136 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 France CHU de Hautepierre Strasbourg, France Germany Universität Heidelberg Heidelberg, Germany 收起 <<
NCT02337062	PONV	Phase 3	Completed	-	United States, Alabama ... 展开 >> Helen Keller Hospital Sheffield, Alabama, United States, 35660 United States, California UCSF School of Medicine San Francisco, California, United States, 94143 United States, Florida Jackson Memorial Hospital Miami, Florida, United States, 33136 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Massachusetts Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 United States, New York Albany Medical Center Hospital Albany, New York, United States, 12208 Stony Brook Medicine Stony Brook, New York, United States, 11794 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 Wake Forest University School of Medicine Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 Ohio State University Columbus, Ohio, United States, 43210 United States, Texas First Street Surgical Center Bellaire, Texas, United States, 77401 Victory Medical Center Houston Houston, Texas, United States, 77004 Memorial Hermann-Memorial City Hospital Houston, Texas, United States, 77024 France University Hospital Besançon, France, 25030 Centre Hospitalier Lyon-Sud Lyon, France, 69495 Centre Hospitalier de Mulhouse Mulhouse, France, 68051 Hopital Foch Paris, France CHU de Hautepierre Strasbourg, France Germany HELIOS Klinikum Aue Aue, Germany, 08280 Universitätsklinikum Bonn Bonn, Germany, 53127 Klinikum Ludwigshafen Ludwigshafen, Germany, 67063 Universitätsmedizin Mainz Mainz, Germany, 55131 Philipps University Marburg, Germany, 35033 University Hospitals of Würzburg Würzburg, Germany 收起 <<
NCT02337062	-		Completed	-	-
NCT01991821	PONV	Phase 3	Completed	-	France ... 展开 >> CHU de Hautepierre Strasbourg, France Germany University Hospitals of Würzburg Würzburg, Germany 收起 <<
NCT01991860	PONV	Phase 3	Completed	-	United States, North Carolina ... 展开 >> Duke Durham, North Carolina, United States 收起 <<
NCT02646566	Postoperative Nausea and Vomit... 展开 >>ing 收起 <<	Phase 3	Completed	-	United States, Florida ... 展开 >> Jackson Memorial Hospital Miami, Florida, United States, 33136 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 Wake Forest University School of Medicine Winston-Salem, North Carolina, United States, 27157 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 France CHU de Hautepierre Strasbourg, France Germany HELIOS Klinikum Aue Aue, Germany, 08280 Universität Heidelberg Heidelberg, Germany Philipps University Marburg, Germany 收起 <<
NCT01991860	-		Completed	-	-
NCT02926859	Schizophrenia	Phase 2	Recruiting	December 2018	Germany ... 展开 >> Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health Recruiting Mannheim, BW, Germany, 68159 Contact: F. Markus Leweke, MD +49 621 1703 ext 2761 leweke@cimh.de Principal Investigator: F. Markus Leweke, MD Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich Not yet recruiting Munich, BY, Germany, 80336 Contact: Peter Falkai, MD Peter.Falkai@med.uni-muenchen.de Principal Investigator: Peter Falkai, MD Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte Recruiting Berlin, B, Germany, 10117 Contact: Henrik Walter, MD, PhD henrik.walter@charite.de Principal Investigator: Henrik Walter, MD Department of Psychiatry Psychotherapy and Psychosomatics, RWTH Aachen Recruiting Aachen, NRW, Germany, 52074 Contact: Tanja Veselinovic, MD tveselinovic@ukaachen.de Principal Investigator: Tanja Veselinovic, MD Dept. of Psychiatry and Psychotherapy Recruiting Cologne, NRW, Germany, 50924 Contact: Frank Jessen, MD frank.jessen@uk-koeln.de Principal Investigator: Frank Jessen, MD 收起 <<
NCT00926965	Tardive Dyskinesia ... 展开 >> Neurocognitive Function 收起 <<	Phase 4	Completed	-	Taiwan ... 展开 >> Yu-Li Veternas Hospital Hualien, Taiwan, 981 收起 <<
NCT01185418	-		Completed	-	Korea, Republic of ... 展开 >> Chonbuk national university hospital Jeonju, Korea, Republic of 收起 <<
NCT01248195	Schizophrenia ... 展开 >> Schizophreniform Disorder Schizoaffective Disorder 收起 <<	Phase 4	Completed	-	-
NCT01029769	Schizophrenia ... 展开 >> Schizoaffective Disorder Schizophreniform Disorder 收起 <<	Not Applicable	Completed	-	Germany ... 展开 >> Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar Munic, Bavaria, Germany, 81675 收起 <<
NCT01154829	Schizophrenia	Not Applicable	Completed	-	Denmark ... 展开 >> Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup Glostrup, Denmark, DK-2600 收起 <<
NCT01454453	Alzheimer's Disease ... 展开 >> Schizophrenia 收起 <<	Phase 4	Terminated(Failure to recruit ... 展开 >>people with very late onset schizophrenia like psychosis) 收起 <<	-	United Kingdom ... 展开 >> Institute of Psychiatry, Kings College London London, United Kingdom, SE58AF 收起 <<
NCT00628290	Schizophrenia	Phase 2	Completed	-	Germany ... 展开 >> University of Cologne, Dept. of Psychiatry and Psychotherapy Cologne, NRW, Germany, 50924 收起 <<
NCT02557984	Addiction	Not Applicable	Completed	-	Switzerland ... 展开 >> University Hospital Zurich, Switzerland, 8091 收起 <<
NCT01446328	Schizophrenia ... 展开 >> Psychotic Disorders 收起 <<	Phase 4	Completed	-	Austria ... 展开 >> Medizinische Universität Innsbruck Innsbruck, Austria, 6020 Norway Haukeland University Hospital Bergen, Norway, 5223 Stavanger University Hospital Stavanger, Norway St. Olavs Hospital Trondheim, Norway 收起 <<
NCT01701258	Major Depressive Disorder (MDD... 展开 >>) History of Childhood Sexual Abuse (CSA) 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> McLean Hospital Belmont, Massachusetts, United States, 02478 Massachusetts General Hospital Boston, Massachusetts, United States, 02114 收起 <<
NCT01701258	-		Completed	-	-
NCT00419653	Schizophrenia	Phase 4	Terminated(Recruitment issues)	-	-
NCT02880995	Schizophrenia	Not Applicable	Unknown	December 2018	-
NCT00956189	Metabolic Syndrome X	Not Applicable	Completed	-	Taiwan ... 展开 >> Yu-Li Hospital Yu-Li, Hualien County, Taiwan, 981 Yu-Li Veterans Hospital Yu-Li, Hualien County, Taiwan, 981 National Taiwan University Hospital Taipei, Taiwan, 10002 收起 <<
NCT00471588	Obsessive-Compulsive Disorder	Phase 1	Completed	-	United Kingdom ... 展开 >> GSK Investigational Site Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ 收起 <<
NCT00761670	Schizophrenia	Phase 4	Completed	-	Hungary ... 展开 >> Sanofi-Aventis Administrative Office Budapest, Hungary 收起 <<
NCT01972711	Schizophrenia	Phase 1	Completed	-	United Kingdom ... 展开 >> Department of Psychiatry, University of Oxford, Warneford Hospital Headington, Oxford, United Kingdom, OX3 7JX University of Manchester, Neuroscience and Psychiatry Unit Manchester, United Kingdom, M13 9PT 收起 <<
NCT02661594	-		Completed	-	-
NCT00534573	Clozapine-induced Hypersalivat... 展开 >>ion 收起 <<	Phase 3	Completed	-	Israel ... 展开 >> Be'er Sheva Mental Health Center, Tirat HaKarmel Mental Health Center Be'er Sheva, Haifa, Israel 收起 <<
NCT00126009	Bipolar Disorder	Phase 2	Completed	-	Czech Republic ... 展开 >> Sanofi-Aventis Prague, Czech Republic France Sanofi-Aventis Paris, France Poland Sanofi-Aventis Warsaw, Poland Slovakia Sanofi-Aventis Bratislava, Slovakia Spain Sanofi-Aventis Barcelona, Spain 收起 <<
NCT00204061	Schizophrenia ... 展开 >> Psychoses 收起 <<	Phase 4	Completed	-	Germany ... 展开 >> Department of Psychiatry and Psycotherapy University of Cologne Cologne, North Rhine-Westphalia, Germany, 50924 收起 <<
NCT02661594	Healthy	Phase 1	Completed	-	-
NCT01160991	Schizophrenia ... 展开 >> Diabetes Insulin Resistance 收起 <<	Not Applicable	Completed	-	Germany ... 展开 >> Central Institute of Mental Health Mannheim, Germany, 68159 收起 <<
NCT01253421	-		Completed	-	-
NCT00245674	Schizophrenia	Phase 4	Completed	-	Belgium ... 展开 >> Sanofi-aventis Diegem, Belgium 收起 <<
NCT01555814	Schizophrenia ... 展开 >> Schizophreniform Disorder Schizoaffective Disorder 收起 <<	Not Applicable	Completed	-	Denmark ... 展开 >> Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup Glostrup, Denmark Glostrup, Denmark 收起 <<
NCT00436371	Schizophrenia	Phase 4	Completed	-	Hong Kong ... 展开 >> Sanofi-Aventis Hong Kong, Hong Kong 收起 <<
NCT01253421	Major Depressive Disorder (MDD... 展开 >>) 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> McLean Hospital Belmont, Massachusetts, United States, 02478 收起 <<
NCT01105481	Treatment-resistant Schizophre... 展开 >>nia 收起 <<	Phase 4	Completed	-	Taiwan ... 展开 >> Bali Psychiatric Center Taipei County, Taiwan Departments of Psychiatry, Tao-yuan Psychiatric Center Tao-Yuan, Taiwan 收起 <<
NCT01609153	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 4	Recruiting	April 2020	Germany ... 展开 >> RWTH Aachen Recruiting Aachen, Germany, 52074 Contact: Tanja Veselinovic, Dr. med. +49-(0)241-8080 ext 0 tveselinovic@ukaachen.de Contact: Marc Augustin, Dr. med. +49-(0)241-8080 ext 166 maugustin@ukaachen.de Rheinhessen Fachklinik Alzey Recruiting Alzey, Germany, 55232 Contact: Anke Brockhaus-Dumke, PD Dr. med. +49-(0)6731 ext 501212 a.brockhaus-dumke@rfk.landeskrankenhaus.de Contact: Siamak Roushanai, Dr. med. +49-(0)6731 ext 501593 s.roushanai@rfk.landeskrankenhaus.de Rhein-Mosel-Fachklinik Andernach Recruiting Andernach, Germany, 56626 Contact: Andreas Konrad, PD Dr. med. +49-(0)2632-407 ext 5534 a.konrad@rmf.landeskrankenhaus.de Contact: Stefan Elsner, Dr. med. +49-(0)2632-407 ext 5412 s.elsner@rmf.landeskrankenhaus.de Bezirkskliniken Schwaben, Bezirkskrankenhaus Augsburg Recruiting Augsburg, Germany, 89156 Contact: Susanne Baumgärtner +49-0821-4803 ext 1021 wissenschaftsabteilung@bkh-augsburg.de Contact: Marianne Bärhold, Dr. +49-0821-4803 ext 3770 wissenschaftsabteilung@bkh-augsburg.de Charite-Universitätsmedizin Berlin Withdrawn Berlin, Germany, 10117 LWL-Klinik Dortmund Recruiting Dortmund, Germany, 44281 Contact: Hans-Jörg Assion, Prof. Dr. +49-(0)231-45092673 hans-joerg.assion@wkp-wl.org Contact: Gerhard Reymann, PD Dr. gerhard.reymann@lwl.org LVR-Klinikum Düsseldorf Recruiting Düsseldorf, Germany, 40629 Contact: Christian Schmidt-KraepelinCordes, Dr. +49-(0)211-922 ext 2783 christian.schmidt-kraepelin@lvr.de Contact: Joachim Cordes, PD Dr. +49-(0)211-922 ext 3402 joachim.cordes@lvr.de Zentrum für Seelische Gesundheit Kreiskliniken Darmstadt-Dieburg Standort: Groß-Umstadt Recruiting Groß-Umstadt, Germany, 64823 Contact: Thomas Wobrock, Prof. MD +49-(0)6078-79 ext 2901 t.wobrock@kreiskliniken-dadi.de Contact: Jens Edinger j.edinger@kreiskliniken-dadi.de Universitätsmedizin Göttingen Recruiting Göttingen, Germany, 37075 Contact: Bernhard Kis, Dr. +49-(0)551-3910114 Bernhard.Kis@med.uni-goettingen.de Contact: David Zilles, Dr. dzilles@gwdg.de Klinik für Psychiatrie, Psychotherapie und Psychosomatik am Bezirkskrankehaus Günzburg Suspended Günzburg, Germany, 89312 Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie Medizinische Hochschule Hannover (MHH) Recruiting Hannover, Germany, 30625 Contact: Kai Kahl, Prof. Dr. 0049511532 ext 2495 kahl.kai@mh-hannover.de Contact: Helge Frieling, Prof. Dr. 0049511532 ext 2495 frieling.helge@mh-hannover.de Universitätsklinikum Heidelberg Withdrawn Heidelberg, Germany, 69115 LVR-Klinikum Köln Recruiting Köln, Germany, 51109 Contact: Dirk Reske, Dr. +49-(0)2218993 ext 797 dirk.reske@lvr.de Contact: Ulrike Reinholz, Dr. +49-(0)2218993 ext 0 ulrike.reinholz@lvr.de LVR-Klinik Langenfeld Recruiting Langenfeld, Germany, 40764 Contact: Andrea Neff, Dr. +49-(0)2173102 ext 0 andrea.neff@lvr.de Contact: Martina Pellio-Blume, Dr. +49-(0)2173102 ext 0 martina.pellio-blume@lvr.de Universitätsklinikum Leipzig, Klinik und Poliklinik für Psychiatrie und Psychotherapie Recruiting Leipzig, Germany, 04103 Contact: Michael Kluge, Dr 00493419724 ext 673 michael.kluge@medizin.uni-leipzig.de Contact: Jens Dietzel, Dr. 00493419724 ext 530 jens.dietzel@medizin.uni-leipzig.de Universitätsmedizin Mainz Klinik für Psychiatrie und Psychotherapie Withdrawn Mainz, Germany, 55131 Zentralinstitut für Seelische Gesundheit Recruiting Mannheim, Germany, 68159 Contact: Gerhard Gründer, Prof. MD +49-(0)621-1703 ext 2911 Gerhard.Gruender@zi-mannheim.de Contact: Mathias Zink, Prof. MD +49-(0)621-1703 ext 2911 Mathias.Zink@zi-mannheim.de LMU München Recruiting München, Germany, 80336 Contact: Peter Falkai, Prof. Dr. +49-(0)89-5160 ext 5501 Peter.Falkai@med.uni-muenchen.de Contact: Berend Malchow, Dr. +49-(0)89-4400 ext 55331 Berend.Malchow@med.uni-muenchen.de TU München Suspended München, Germany, 81675 Bezirksklinikum Regensburg, Klinik für Psychiatrie und Psychotherapie Recruiting Regensburg, Germany, 93053 Contact: Berthold Langguth, PD Dr. med. +49-(0)941941 ext 2099 berthold.langguth@medbo.de Contact: Elmar Frank, Dr. +49-(0)941941 ext 0 elmar.frank@medbo.de Universitätsklinikum Würzburg Withdrawn Würzburg, Germany, 97080 收起 <<
NCT00331981	Schizophrenia	Phase 4	Completed	-	Korea, Republic of ... 展开 >> Sanofi-Aventis Seoul, Korea, Republic of 收起 <<
NCT01615185	Schizophrenia	Phase 4	Terminated	-	Taiwan ... 展开 >> Kai-Suan Psychiatric Hospital Kaohsiung, Taiwan, 802 收起 <<
NCT01795183	Schizophrenia	Phase 4	Completed	-	China ... 展开 >> Sanofi-Aventis Administrative Office Beijing, China 收起 <<
NCT01448499	Schizophrenia ... 展开 >> Treatment Resistant Disorders 收起 <<	Not Applicable	Withdrawn	-	Israel ... 展开 >> Geha Mental Health Center Petach-Tikva, Israel, 49000 收起 <<
NCT02095938	Schizophrenia ... 展开 >> Schizophreniform Disorder 收起 <<	Phase 4	Unknown	December 2015	-
NCT01246232	Schizophrenia	Phase 4	Completed	-	United Kingdom ... 展开 >> University College London London, United Kingdom, NW3 2PF Imperial College London London, United Kingdom, W6 8LN University of Manchester Manchester, United Kingdom, M13 9WL 收起 <<

氨磺必利 /Amisulpride {[allProObj[0].p_purity_real_show]}

Amisulpride 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Amisulpride 质控信息

Amisulpride 生物活性

Amisulpride 临床研究

Amisulpride 参考文献

Amisulpride 实验方案

Amisulpride 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

氨磺必利 /Amisulpride {[allProObj[0].p_purity_real_show]}

Amisulpride 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Amisulpride 质控信息

Amisulpride 生物活性

Amisulpride 临床研究

Amisulpride 参考文献

Amisulpride 实验方案

Amisulpride 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Amisulpride 纯度/质量文件产品仅供科研